Loading . . .
  • About Us
    • Mission & Vision
    • Strategic Plan
    • Board of Directors
    • Staff
  • Resources
    • Guidelines
    • List of Recommended Devices
    • Professional Certification Program
    • Educational Resources
  • Advocacy
  • Membership
  • News/eINFO
  • Events
    • General Information
    • 2025 Virtual Congress
    • May Measurement Month
    • June Webinar
  • Awards
    • General awards
    • MMM contest winners
  • Contact Us
  • Donate
  • Français

Treatment of hypertension in association with nondiabetic chronic kidney disease

Recommendations

  • For patients with hypertension and proteinuric chronic kidney disease (urinary protein level > 150 mg in 24 hours or albumin to creatinine ratio > 30 mg/mmol), initial therapy should be with an ACE inhibitor (Grade A) or an ARB (Grade B; revised recommendation).
  • In most cases, combination therapy with other antihyper-tensive agents might be needed to reach target BP levels (Grade D).
  • The combination of an ACE inhibitor and ARB is not recommended for patients with chronic kidney disease (Grade B; revised recommendation).
  • About Us
    • Mission & Vision
    • Strategic Plan
    • Position Statements
    • Board of Directors
    • Staff
  • Resources
    • Guidelines
    • List of Recommended Devices
    • Professional Certification Program
    • Educational Resources
  • About Us
  • Resources
  • Advocacy
  • Membership
  • News/eINFO
  • Events
  • Awards
  • Contact Us
  • Donate
  • Français

Privacy Policy | Terms of Use

© 2025 Hypertension Canada. All rights reserved. Unauthorized
use prohibited. Hypertension Canada does not provide medical
advice, diagnosis or treatment.